Coherus Oncology, Inc.
CHRS · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $266,960 | $257,244 | $211,042 | $326,551 |
| % Growth | 3.8% | 21.9% | -35.4% | – |
| Cost of Goods Sold | $117,553 | $158,992 | $70,083 | $57,591 |
| Gross Profit | $149,407 | $98,252 | $140,959 | $268,960 |
| % Margin | 56% | 38.2% | 66.8% | 82.4% |
| R&D Expenses | $93,336 | $109,436 | $199,358 | $363,105 |
| G&A Expenses | $139,538 | $174,715 | $187,981 | $161,013 |
| SG&A Expenses | $150,438 | $185,615 | $198,481 | $169,713 |
| Sales & Mktg Exp. | $10,900 | $10,900 | $10,500 | $8,700 |
| Other Operating Expenses | $17,300 | $6,400 | $0 | $0 |
| Operating Expenses | $261,074 | $301,451 | $397,839 | $532,818 |
| Operating Income | -$111,667 | -$203,199 | -$256,880 | -$263,858 |
| % Margin | -41.8% | -79% | -121.7% | -80.8% |
| Other Income/Exp. Net | $140,174 | -$35,073 | -$34,874 | -$23,242 |
| Pre-Tax Income | $28,507 | -$238,272 | -$291,754 | -$287,100 |
| Tax Expense | $0 | -$380 | $0 | $0 |
| Net Income | $28,507 | -$237,892 | -$291,754 | -$287,100 |
| % Margin | 10.7% | -92.5% | -138.2% | -87.9% |
| EPS | 0.25 | -2.53 | -3.76 | -3.81 |
| % Growth | 109.9% | 32.7% | 1.3% | – |
| EPS Diluted | 0.25 | -2.53 | -3.76 | -3.81 |
| Weighted Avg Shares Out | 114,554 | 94,163 | 77,630 | 75,450 |
| Weighted Avg Shares Out Dil | 114,830 | 94,163 | 77,630 | 75,450 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $27,158 | $40,542 | $32,474 | $22,959 |
| Depreciation & Amortization | $5,276 | $3,791 | $3,699 | $3,454 |
| EBITDA | $60,941 | -$193,939 | -$255,581 | -$260,687 |
| % Margin | 22.8% | -75.4% | -121.1% | -79.8% |